WG
ELVN icon

Winton Group’s Enliven Therapeutics ELVN Stock Holding History

Winton Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
+4,495
New +$191K 0.01% 974
2025
Q4 		– Sell
-16,458
Closed -$337K – 973
2025
Q3 		$337K Buy
+16,458
New +$332K 0.01% 616

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Winton Group's ELVN Position: Q2 2026 in Review

Winton Group opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 4,495 shares worth $228K. The stake represents 0.01% of the portfolio and ranks #974 among its holdings. This is a return to the name: Winton Group previously reported a position in ELVN as recently as Q3 2025.

Winton Group first reported a position in ELVN in Q3 2025 and has held it in 2 quarters since. The position peaked at $337K in Q3 2025. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Winton Group held 4,495 shares of Enliven Therapeutics worth $228K as of Q2 2026.
  • Enliven Therapeutics was a new Winton Group position in Q2 2026.
  • Enliven Therapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #974 holding.
  • Winton Group first reported a position in Enliven Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Winton Group's Enliven Therapeutics position peaked at $337K in Q3 2025.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.